Announcements Trials
Browse Landscape

Status

Temporarily not available 1

Sponsor Class

OTHER 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Conditions

KRAS G12V Mutant Advanced Epithelial Cancers 1

Interventions

3-Iodobenzylguanidine 2Gemcitabine 2Powders 2Suspensions 2balstilimab 2leronlimab 2ruxolitinib 2talquetamab 2Abiraterone Acetate 1Alpelisib 1Androgen Antagonists 1Asparaginase 1Bone Marrow Transplantation 1Capecitabine 1Cyclophosphamide 1Docetaxel 1Eflornithine 1FANG vaccine 1HMPL-013 1Hydrocortisone 1Immunotherapy, Adoptive 1Insulin Infusion Systems 1LY3023414 1Magnetic Resonance Spectroscopy 1Methionine 1Nivolumab 1Paclitaxel 1Peripheral Blood Stem Cell Transplantation 1Prednisolone 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Insulin Infusion Systems × 1 year × Clear all
NCT05389514 2025-11-20

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Providence Health & Services

Temporarily not available

KRAS G12V Mutant Advanced Epithelial Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡